This video—part 3 of the 5-part Population Health Management (PHM) series—discusses the PHM approach to care within a large health care system. Dr. Bradley Eilerman, MD, discusses the steps crucial to successful PHM implementation, the value of the comprehensive care team, and the impact that collected patient data can have on future health care dissemination.
- Fiasp® (insulin aspart injection) 100 U/mL
- Glucagen® (glucagon) for injection 1 mg/mL
- Levemir® (insulin detemir injection) 100 Units/mL
- Novolin® N (isophane insulin human suspension) 100 U/mL
- Novolin® R (insulin human injection) 100 U/mL
- Novolin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection) 100 U/mL
- NovoLog® (insulin aspart injection) 100 units/mL
- NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) 100 units/mL
- Ozempic® (semaglutide) injection 0.5 mg or 1 mg
- Tresiba® (insulin degludec injection) 100 units/mL, 200 units/mL
- Victoza® (liraglutide) injection 1.2 mg or 1.8 mg
- Vagifem® (estradiol vaginal inserts) 10 mcg
- Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL
- Rybelsus® (semaglutide) tablets 7 mg or 14 mg
- Saxenda® (liraglutide) injection 3 mg
NovoMedLink
For US Health Care Professionals
